A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non- Hodgkin's lymphoma

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2392-2398

  Grossbard, Michael L ^a   Multani, Pratik S ^a   Freedman, Arnold S ^b   O'Day, Steven ^b   Gribben, John G ^b   Rhuda, Catherine ^b   Neuberg, Donna ^b   Nadler, Lee M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; IMMUNOTOXIN; RICIN;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, HETEROPHILE; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RICIN;

EID: 0032852320     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Takvorian, T., Canellos, G. P., Ritz, J., Freedman, A. S., Anderson, K. C., Mauch, P., Tarbell, N., Coral, F., Daley, H., Yeap, B., Schlossman, S. F., and Nadler, L. M. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N. Engl. J. Med., 316: 1499-1505, 1987.
2. Philip, T., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J. Y., Colombat, P., Goldstone, A. H., Gorin, N. C., Flesh, M., Laporte, J-P., Maraninchi, D., Pico, J., Bosley, A., Anderson, C., Schots, R., Biron, P., Cabanillas, F., and Dicke, K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med., 316: 1493-1498, 1987.
3. Brenner, M. K., Rill, D. R., Moen, R. C., Krance, R. A., Mirro, J., Jr., Anderson, W. F., and Ihle, J. N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet, 341: 85-86, 1993.
4. Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S., Ellerson, D., Goldberg, L., Thomas, M., Janicek, K., Anderson, W. F., Mester, J., Korbling, M., Durett, A., Moen, R., Besenson, R., Meimfeld, S., Mamer, J., Calvert, L., Tibbits, P., Talpaz, M., Kantarjian, M., Champlin, R., and Reading, C. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood, 83: 3068-3076, 1994.
5. Grossbard, M. L., Freedman, A. S., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L., Spector, N., Dear, K., Lambert, J. M., Blättler, W. A., Taylor, J. A., and Nadler, L. M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a Phase I trial of daily bolus infusion. Blood, 79: 576-585, 1992.
6. Grossbard, M. L., Lambert, J. M., Goldmacher, V. S., Spector, N. L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J. A., Blättler, W. A., Epstein, C. L., and Nadler, L. M. Anti-B4-blocked ricin: a Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol., 11: 726-737, 1993.
7. Lambert, J. M., Goldmacher, V. S., Collinson, A. R., Nadler, L. M., and Blättler, W. A. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res., 51: 6236-6242, 1991.
8. El-Kareh, A. W., Braunstein, S. L., and Secomb, T. W. Effect of cell arrangement and interstitial volume fraction on the diffusivity of monoclonal antibodies in tissue. Biophys. J., 64: 1638-1646, 1993.
9. Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res., 50 (Suppl.): 814s-819s, 1990.
10. Sedlacek, H-H., Seemann, G., Hoffman, D., Czech, J., Lorenz, P., Kolar, C., and Bosslet, K. Antibodies as carriers of cytotoxicity. In: H. Huber and W. Queiβer (eds.), Contributions to Oncology, Vol. 43. Basel: Karger, 1992.
11. Multani, P. S., O'Day, S., Nadler, L. M., and Grossbard, M. L. Phase II clinical trial of bolus infusion Anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res., 4: 2599-2604, 1998.
12. Grossbard, M. L., Gribben, J. G., Freedman, A. S., Lambert, J. M., Kinsella, J., Rabinowe, S. N., Eliseo, L., Taylor, J. A., Blättler, W. A., Epstein, C. L., and Nadler, L. M. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood, 81: 2263-2271, 1993.
13. Lambert, J. M., McIntyre, G., Gauthier, M. N., Zullo, D., Rao, V., Sleeves, R. M., Goldmacher, V. S., and Blättler, W. A. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry, 30: 3234-3247, 1991.
14. Gribben, J. G., Freedman, A. S., Neuberg, D., Roy, D. C., Blake, K. W., Woo, S. D., Grossbard, M. L., Rabinowe, S. N., Coral, F., Freeman, G. J., Ritz, J., and Nadler, L. M. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med., 325: 1525-1533, 1991.
15. Rabinowe, S. N., Soiffer, R. J., Tarbell, N. J., Neuberg, D., Freedman, A. S., Seifter, J., Blake, K. W., Gribben, J. G., Anderson, K. C., Takvorian, T., Ritz, J., and Nadler, L. M. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood, 77: 1837-1844, 1991.
16. Schenkein, D. P., Dixon, P., Desforges, J. F., Berkman, E., Erban, J. K., Ascensao, J. L., and Miller, K. B. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon α-2b for patients with lymphoma and Hodgkin's disease. J. Clin. Oncol., 12: 2423-2431, 1994.
17. Nagler, A., Ackerstein, A., Or, R., Naparstek, E., and Slavin, S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients postautologous marrow or stem cell transplantation. Blood, 89: 3951-3959, 1997.
18. Soiffer, R. J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F., and Ritz, J. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 79: 517-526, 1992.
19. Higuchi, C. M., Thompson, J. A., Petersen, F. B., Buckner, C. D., and Fefer, A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood, 77: 2561-2568, 1991.
20. Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P. E., Uhr, J. W., and Vitetta, E. S. A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82: 2624-2633, 1993.
21. Conry, R. M., Khazaeli, M. B., Saleh, M. N., Ghetie, V., Vitetta, E. S., Liu, T., and LoBuglio, A. F. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J. Immunother. Emphasis Tumor Immunol., 18: 231-241, 1995.
22. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R. H., Figg, W. D., Stetler-Stevenson, M., Jain, V., Jaffe, E. S., Solomon, D., Lush, R. M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J. W., and Vitetta, E. S. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood, 88: 1188-1197, 1996.
23. Grossbard, M. L., Lambert, J. M., Goldmacher, V. S., Blättler, W. A., and Nadler, L. M. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin. Cancer Res., 52: 4200-4207, 1992.
24. Grossbard, M. L., Niedzwiecki, D., Nadler, L. M., Fruchtman, S. M., Schuster, M., Pecora, A., Lazarus, H. M., Johnson, J., Peterson, B. A., and Hurd, D. D. Anti-B4-blocked ricin (Anti-B4-bR) adjuvant therapy post-autologous bone marrow transplant (ABMT) (CALGB 9254): a Phase III Intergroup study. Proc. Am. Soc. Clin. Oncol., 17: 3a, 1998.
25. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., and Levy, R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90: 2188-2195, 1997.
26. McLaughlin, P., Grillo-Lopez, A. J., Czuczman, M., Link, B. K., Davis, T. A., Dillman, R. O., Ho, A. D., Bennett, J. M., Heyman, M. R., Schilder, R. J., Cabanillas, F., Dallaire, B. K., and White, C. A. IDEC-C2B8 (rituximab): clinical activity in clinically chemoresistant (CCRD) low-grade or follicular lymphoma (LG/F NHL) and in patients (pts) relapsing after anthracycline therapy (ANTHRA-RX) or ABMT. Proc. Am. Soc. Clin. Oncol., 55: 16a, 1997.